港股異動 | 諾輝健康-B(6606.HK)漲約4% 618期間旗下常衞清累計銷售量突破5000份
格隆匯6月23日丨諾輝健康-B(6606.HK)漲約4%,報80港元,總市值345億港元。日前,諾輝健康發佈“618直營電商戰報”。報吿顯示,今年6月1日至6月18日,根據京東商智和生意參謀統計數據,其旗下常衞清累計銷售量突破5000份。同時,諾輝健康京東旗艦店獲得618期間京東基因檢測類目行業銷售額、單品銷售額雙冠軍。此外,諾輝健康近日還首次聯合快手健康和小荷健康發起“腸道健康,防癌早篩”的話題徵集,其中“防癌早篩在快手”的話題上線一週累計獲4167.7萬次播放量。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.